| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 62 | 2024 | 2903 | 7.040 |
Why?
|
| Down Syndrome | 22 | 2023 | 227 | 6.610 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 17 | 2024 | 513 | 2.160 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 11 | 2023 | 331 | 2.000 |
Why?
|
| Child | 84 | 2024 | 30559 | 1.110 |
Why?
|
| Leukemia | 6 | 2023 | 1719 | 1.000 |
Why?
|
| Ikaros Transcription Factor | 4 | 2021 | 53 | 0.950 |
Why?
|
| Methotrexate | 9 | 2024 | 1025 | 0.940 |
Why?
|
| Leukemoid Reaction | 1 | 2023 | 12 | 0.890 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 2023 | 102 | 0.850 |
Why?
|
| Leukemia, Myeloid, Acute | 10 | 2023 | 7265 | 0.840 |
Why?
|
| Lymphocyte Count | 3 | 2022 | 485 | 0.800 |
Why?
|
| Penetrance | 1 | 2020 | 134 | 0.700 |
Why?
|
| Child, Preschool | 37 | 2024 | 17061 | 0.700 |
Why?
|
| Integrases | 1 | 2020 | 256 | 0.650 |
Why?
|
| Infant | 29 | 2024 | 13999 | 0.620 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 14 | 2023 | 16689 | 0.570 |
Why?
|
| Humans | 104 | 2024 | 270740 | 0.550 |
Why?
|
| Neoplasm, Residual | 6 | 2023 | 1754 | 0.540 |
Why?
|
| Philadelphia Chromosome | 2 | 2020 | 852 | 0.530 |
Why?
|
| Antimetabolites, Antineoplastic | 5 | 2024 | 1347 | 0.530 |
Why?
|
| Mycoses | 2 | 2021 | 393 | 0.510 |
Why?
|
| Adolescent | 35 | 2024 | 32767 | 0.510 |
Why?
|
| Acute Disease | 8 | 2023 | 2493 | 0.480 |
Why?
|
| Prognosis | 26 | 2024 | 22505 | 0.460 |
Why?
|
| Lymphoma | 1 | 2023 | 1519 | 0.460 |
Why?
|
| Disease-Free Survival | 15 | 2024 | 10265 | 0.450 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 1402 | 0.440 |
Why?
|
| Self Report | 1 | 2017 | 796 | 0.420 |
Why?
|
| Genome-Wide Association Study | 6 | 2021 | 2351 | 0.410 |
Why?
|
| Neurotoxicity Syndromes | 2 | 2024 | 126 | 0.400 |
Why?
|
| B-Lymphocytes | 4 | 2021 | 1424 | 0.400 |
Why?
|
| Receptors, Cytokine | 3 | 2022 | 179 | 0.400 |
Why?
|
| Steroids | 1 | 2013 | 372 | 0.380 |
Why?
|
| Janus Kinase 2 | 4 | 2017 | 754 | 0.380 |
Why?
|
| Bacterial Infections | 1 | 2014 | 510 | 0.360 |
Why?
|
| Salvage Therapy | 1 | 2019 | 2123 | 0.360 |
Why?
|
| Antineoplastic Agents | 8 | 2023 | 14617 | 0.350 |
Why?
|
| Anti-Infective Agents | 1 | 2014 | 466 | 0.350 |
Why?
|
| Male | 53 | 2024 | 128315 | 0.350 |
Why?
|
| Recurrence | 9 | 2024 | 4878 | 0.340 |
Why?
|
| Polymorphism, Single Nucleotide | 8 | 2021 | 4644 | 0.340 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 8 | 2023 | 7044 | 0.340 |
Why?
|
| Young Adult | 19 | 2024 | 22251 | 0.340 |
Why?
|
| Transcription Factors | 3 | 2020 | 5438 | 0.340 |
Why?
|
| Gene Deletion | 3 | 2021 | 1474 | 0.320 |
Why?
|
| Gene Rearrangement | 3 | 2020 | 813 | 0.320 |
Why?
|
| Remission Induction | 2 | 2012 | 3656 | 0.320 |
Why?
|
| Leukemia, Biphenotypic, Acute | 2 | 2019 | 49 | 0.320 |
Why?
|
| Treatment Failure | 1 | 2012 | 1430 | 0.310 |
Why?
|
| Female | 51 | 2024 | 148940 | 0.310 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2023 | 10400 | 0.300 |
Why?
|
| Metabolome | 2 | 2021 | 355 | 0.300 |
Why?
|
| Gene Expression Profiling | 2 | 2011 | 5149 | 0.290 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2008 | 632 | 0.290 |
Why?
|
| Mutation | 9 | 2023 | 15912 | 0.280 |
Why?
|
| Residence Characteristics | 2 | 2020 | 356 | 0.280 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2021 | 5776 | 0.280 |
Why?
|
| DNA Methylation | 3 | 2021 | 2765 | 0.280 |
Why?
|
| Metabolomics | 2 | 2021 | 504 | 0.280 |
Why?
|
| Genomics | 5 | 2024 | 2835 | 0.270 |
Why?
|
| Chromosome Aberrations | 4 | 2023 | 2035 | 0.270 |
Why?
|
| Point Mutation | 1 | 2008 | 788 | 0.260 |
Why?
|
| Dasatinib | 2 | 2020 | 881 | 0.250 |
Why?
|
| Stem Cell Transplantation | 1 | 2012 | 1418 | 0.240 |
Why?
|
| Laxatives | 1 | 2024 | 17 | 0.240 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2024 | 55 | 0.230 |
Why?
|
| Mercaptopurine | 3 | 2019 | 130 | 0.230 |
Why?
|
| Exome | 3 | 2022 | 1248 | 0.230 |
Why?
|
| Histones | 1 | 2011 | 1513 | 0.220 |
Why?
|
| Cell Proliferation | 5 | 2021 | 7238 | 0.220 |
Why?
|
| PAX5 Transcription Factor | 2 | 2024 | 47 | 0.220 |
Why?
|
| Constipation | 1 | 2024 | 187 | 0.220 |
Why?
|
| Genotype | 6 | 2021 | 4252 | 0.210 |
Why?
|
| Immunoglobulins | 1 | 2023 | 286 | 0.200 |
Why?
|
| gamma-Glutamyl Hydrolase | 1 | 2021 | 10 | 0.190 |
Why?
|
| Burkitt Lymphoma | 1 | 2024 | 350 | 0.190 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2021 | 85 | 0.180 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2018 | 5408 | 0.180 |
Why?
|
| Gene Frequency | 2 | 2021 | 1246 | 0.180 |
Why?
|
| Nervous System Neoplasms | 1 | 2020 | 35 | 0.180 |
Why?
|
| Osteosarcoma | 1 | 2008 | 950 | 0.180 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2022 | 201 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2021 | 98 | 0.180 |
Why?
|
| Electronic Health Records | 2 | 2024 | 850 | 0.180 |
Why?
|
| Monocytes | 2 | 2023 | 790 | 0.180 |
Why?
|
| Dried Blood Spot Testing | 1 | 2020 | 22 | 0.170 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2021 | 257 | 0.170 |
Why?
|
| Ubiquitin-Specific Peptidase 7 | 1 | 2019 | 40 | 0.170 |
Why?
|
| Mice | 10 | 2023 | 35600 | 0.170 |
Why?
|
| Alleles | 3 | 2021 | 2600 | 0.170 |
Why?
|
| Risk Factors | 9 | 2023 | 17888 | 0.160 |
Why?
|
| Vehicle Emissions | 1 | 2019 | 25 | 0.160 |
Why?
|
| Quantitative Trait Loci | 1 | 2021 | 384 | 0.160 |
Why?
|
| Diploidy | 2 | 2008 | 116 | 0.160 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2020 | 204 | 0.160 |
Why?
|
| Social Class | 1 | 2020 | 324 | 0.160 |
Why?
|
| Imatinib Mesylate | 2 | 2020 | 1691 | 0.150 |
Why?
|
| Homozygote | 1 | 2021 | 772 | 0.150 |
Why?
|
| Retrospective Studies | 14 | 2024 | 39890 | 0.150 |
Why?
|
| Treatment Outcome | 10 | 2023 | 33737 | 0.150 |
Why?
|
| Neonatal Screening | 1 | 2020 | 188 | 0.150 |
Why?
|
| Infant, Newborn | 7 | 2022 | 8699 | 0.150 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2013 | 1020 | 0.150 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2018 | 112 | 0.150 |
Why?
|
| DNA-Binding Proteins | 3 | 2021 | 5002 | 0.150 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2018 | 162 | 0.150 |
Why?
|
| Maternal Exposure | 1 | 2019 | 154 | 0.150 |
Why?
|
| Cytogenetic Analysis | 2 | 2021 | 574 | 0.150 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2019 | 341 | 0.150 |
Why?
|
| Karyotyping | 4 | 2015 | 1063 | 0.150 |
Why?
|
| Software | 1 | 2024 | 1355 | 0.140 |
Why?
|
| Air Pollutants | 1 | 2019 | 135 | 0.140 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 625 | 0.140 |
Why?
|
| Health Status Disparities | 1 | 2020 | 318 | 0.140 |
Why?
|
| MAP Kinase Kinase 7 | 1 | 2016 | 17 | 0.140 |
Why?
|
| Animals | 12 | 2023 | 61956 | 0.140 |
Why?
|
| Leukemia, Myeloid | 2 | 2013 | 993 | 0.140 |
Why?
|
| Bone Marrow | 2 | 2022 | 2441 | 0.140 |
Why?
|
| Hematologic Neoplasms | 2 | 2021 | 1956 | 0.140 |
Why?
|
| Models, Theoretical | 1 | 2021 | 799 | 0.140 |
Why?
|
| Induction Chemotherapy | 1 | 2020 | 670 | 0.140 |
Why?
|
| HEK293 Cells | 1 | 2021 | 1461 | 0.140 |
Why?
|
| Lymphoma, B-Cell | 1 | 2023 | 929 | 0.130 |
Why?
|
| Case-Control Studies | 6 | 2024 | 6224 | 0.130 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 1267 | 0.130 |
Why?
|
| Survival Rate | 7 | 2021 | 12541 | 0.130 |
Why?
|
| Registries | 2 | 2022 | 2211 | 0.130 |
Why?
|
| Acute Kidney Injury | 1 | 2023 | 761 | 0.130 |
Why?
|
| Gene Fusion | 1 | 2017 | 214 | 0.130 |
Why?
|
| Smad Proteins | 1 | 2015 | 82 | 0.130 |
Why?
|
| Neoplasms | 5 | 2024 | 15927 | 0.130 |
Why?
|
| Immune Evasion | 1 | 2015 | 76 | 0.130 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 751 | 0.120 |
Why?
|
| Follow-Up Studies | 8 | 2024 | 15218 | 0.120 |
Why?
|
| Bone Neoplasms | 1 | 2008 | 2665 | 0.120 |
Why?
|
| Genome, Human | 2 | 2021 | 1888 | 0.120 |
Why?
|
| Cognition Disorders | 1 | 2020 | 762 | 0.120 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2016 | 277 | 0.120 |
Why?
|
| Adult | 13 | 2023 | 82040 | 0.120 |
Why?
|
| Incidence | 5 | 2024 | 5824 | 0.120 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2021 | 1367 | 0.110 |
Why?
|
| Proportional Hazards Models | 3 | 2018 | 5101 | 0.110 |
Why?
|
| Base Sequence | 2 | 2011 | 5437 | 0.110 |
Why?
|
| Risk | 2 | 2023 | 1939 | 0.110 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2015 | 683 | 0.110 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 1441 | 0.110 |
Why?
|
| Cell Line | 3 | 2013 | 5338 | 0.110 |
Why?
|
| Cell Differentiation | 2 | 2022 | 4116 | 0.110 |
Why?
|
| Leukocyte Count | 2 | 2011 | 735 | 0.110 |
Why?
|
| Cytosol | 1 | 2013 | 267 | 0.110 |
Why?
|
| Electronics | 2 | 2023 | 62 | 0.110 |
Why?
|
| Repressor Proteins | 1 | 2021 | 1718 | 0.110 |
Why?
|
| Risk Assessment | 2 | 2024 | 6764 | 0.110 |
Why?
|
| Protein Kinases | 1 | 2017 | 902 | 0.100 |
Why?
|
| Biomarkers | 2 | 2021 | 5051 | 0.100 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2013 | 107 | 0.100 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2014 | 691 | 0.100 |
Why?
|
| Age Distribution | 1 | 2013 | 727 | 0.100 |
Why?
|
| Texas | 5 | 2022 | 6449 | 0.100 |
Why?
|
| Cellulitis | 1 | 2011 | 80 | 0.100 |
Why?
|
| DNA | 1 | 2020 | 3050 | 0.100 |
Why?
|
| Janus Kinase 3 | 1 | 2011 | 47 | 0.100 |
Why?
|
| Tumor Microenvironment | 2 | 2020 | 3035 | 0.100 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2015 | 2313 | 0.090 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 855 | 0.090 |
Why?
|
| Cohort Studies | 5 | 2024 | 9470 | 0.090 |
Why?
|
| Creatinine | 2 | 2023 | 529 | 0.090 |
Why?
|
| Cell Line, Tumor | 3 | 2021 | 14849 | 0.090 |
Why?
|
| Central Nervous System | 2 | 2023 | 451 | 0.090 |
Why?
|
| Dexamethasone | 3 | 2021 | 1516 | 0.090 |
Why?
|
| Clinical Trials as Topic | 3 | 2022 | 3844 | 0.090 |
Why?
|
| Age Factors | 3 | 2021 | 5457 | 0.090 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2013 | 383 | 0.090 |
Why?
|
| Janus Kinase 1 | 1 | 2011 | 125 | 0.090 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2013 | 714 | 0.090 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2023 | 2486 | 0.090 |
Why?
|
| Transforming Growth Factor beta | 1 | 2015 | 1109 | 0.090 |
Why?
|
| Killer Cells, Natural | 1 | 2015 | 965 | 0.090 |
Why?
|
| Dendritic Cells | 2 | 2013 | 1110 | 0.090 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2009 | 29 | 0.090 |
Why?
|
| Antigens, Neoplasm | 2 | 2013 | 1580 | 0.080 |
Why?
|
| Neoplasm Proteins | 2 | 2018 | 3345 | 0.080 |
Why?
|
| DNA Primers | 1 | 2011 | 1496 | 0.080 |
Why?
|
| Asparaginase | 2 | 2020 | 196 | 0.080 |
Why?
|
| Leucovorin | 2 | 2020 | 345 | 0.080 |
Why?
|
| Phosphoproteins | 1 | 2013 | 1138 | 0.080 |
Why?
|
| Membrane Glycoproteins | 1 | 2013 | 1094 | 0.080 |
Why?
|
| RNA-Binding Proteins | 1 | 2013 | 1017 | 0.070 |
Why?
|
| Radiation Dosage | 1 | 2012 | 1042 | 0.070 |
Why?
|
| Prednisone | 2 | 2020 | 1034 | 0.070 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 1199 | 0.070 |
Why?
|
| Neutropenia | 1 | 2011 | 1006 | 0.070 |
Why?
|
| Bayes Theorem | 2 | 2023 | 1060 | 0.070 |
Why?
|
| Gene Editing | 2 | 2021 | 229 | 0.070 |
Why?
|
| Apoptosis | 2 | 2018 | 7757 | 0.070 |
Why?
|
| MicroRNAs | 1 | 2020 | 2887 | 0.070 |
Why?
|
| Immunophenotyping | 3 | 2019 | 1726 | 0.070 |
Why?
|
| Single-Cell Analysis | 2 | 2021 | 557 | 0.070 |
Why?
|
| Pyrazoles | 1 | 2015 | 1546 | 0.070 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2018 | 2635 | 0.070 |
Why?
|
| Vincristine | 2 | 2021 | 1583 | 0.060 |
Why?
|
| Polyethylene Glycols | 2 | 2020 | 654 | 0.060 |
Why?
|
| Enzyme Activation | 1 | 2008 | 1810 | 0.060 |
Why?
|
| Data Curation | 1 | 2024 | 12 | 0.060 |
Why?
|
| Chromosome Deletion | 1 | 2009 | 1049 | 0.060 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2018 | 586 | 0.060 |
Why?
|
| Genetic Markers | 1 | 2008 | 1075 | 0.060 |
Why?
|
| Cell Cycle Proteins | 1 | 2013 | 2115 | 0.060 |
Why?
|
| Odds Ratio | 2 | 2019 | 2311 | 0.060 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2009 | 1642 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 3 | 2016 | 5759 | 0.060 |
Why?
|
| France | 1 | 2023 | 122 | 0.060 |
Why?
|
| Flow Cytometry | 2 | 2023 | 3045 | 0.060 |
Why?
|
| Hodgkin Disease | 1 | 2012 | 1485 | 0.050 |
Why?
|
| Sex Factors | 1 | 2008 | 2184 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2012 | 2197 | 0.050 |
Why?
|
| Amino Acid Sequence | 1 | 2009 | 4567 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 3 | 2020 | 7100 | 0.050 |
Why?
|
| Cytarabine | 2 | 2020 | 2014 | 0.050 |
Why?
|
| Genes, Immunoglobulin | 1 | 2023 | 86 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2015 | 3658 | 0.050 |
Why?
|
| Naphthyridines | 1 | 2023 | 45 | 0.050 |
Why?
|
| WT1 Proteins | 2 | 2013 | 107 | 0.050 |
Why?
|
| Censuses | 1 | 2022 | 15 | 0.050 |
Why?
|
| Hypokalemia | 1 | 2022 | 61 | 0.050 |
Why?
|
| Cell Survival | 1 | 2008 | 3063 | 0.050 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 9039 | 0.050 |
Why?
|
| Fibroblasts | 1 | 2008 | 1654 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2008 | 3476 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2013 | 9292 | 0.050 |
Why?
|
| Logistic Models | 2 | 2019 | 3444 | 0.050 |
Why?
|
| Entropy | 1 | 2021 | 36 | 0.050 |
Why?
|
| Stochastic Processes | 1 | 2021 | 51 | 0.050 |
Why?
|
| Models, Animal | 1 | 2004 | 657 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 1 | 2008 | 2573 | 0.050 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2021 | 115 | 0.050 |
Why?
|
| Obesity | 1 | 2013 | 2904 | 0.050 |
Why?
|
| Oncogenes | 1 | 2004 | 699 | 0.040 |
Why?
|
| Consolidation Chemotherapy | 1 | 2021 | 153 | 0.040 |
Why?
|
| T-Lymphocytes | 2 | 2023 | 3949 | 0.040 |
Why?
|
| T-Cell Acute Lymphocytic Leukemia Protein 1 | 1 | 2019 | 10 | 0.040 |
Why?
|
| Thyroid Diseases | 1 | 2020 | 85 | 0.040 |
Why?
|
| Genes, Dominant | 1 | 2021 | 356 | 0.040 |
Why?
|
| Neuropsychological Tests | 1 | 2024 | 1145 | 0.040 |
Why?
|
| Injections, Spinal | 1 | 2020 | 273 | 0.040 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2021 | 214 | 0.040 |
Why?
|
| Carbohydrate Metabolism | 1 | 2019 | 70 | 0.040 |
Why?
|
| Genes, p16 | 1 | 2019 | 132 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2013 | 3557 | 0.040 |
Why?
|
| Genotyping Techniques | 1 | 2019 | 164 | 0.040 |
Why?
|
| Forecasting | 1 | 2022 | 702 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2008 | 4960 | 0.040 |
Why?
|
| Transcriptome | 2 | 2019 | 1963 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2015 | 2471 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2008 | 6256 | 0.040 |
Why?
|
| GATA3 Transcription Factor | 1 | 2019 | 144 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2024 | 775 | 0.040 |
Why?
|
| Hydrocortisone | 1 | 2020 | 404 | 0.040 |
Why?
|
| United States | 3 | 2021 | 15861 | 0.040 |
Why?
|
| Luciferases | 1 | 2019 | 460 | 0.040 |
Why?
|
| Hospitals, Pediatric | 1 | 2023 | 799 | 0.040 |
Why?
|
| Mucositis | 1 | 2019 | 149 | 0.040 |
Why?
|
| Air Pollution | 1 | 2019 | 83 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2019 | 749 | 0.040 |
Why?
|
| World Health Organization | 1 | 2019 | 327 | 0.040 |
Why?
|
| Pyrophosphatases | 1 | 2018 | 49 | 0.040 |
Why?
|
| Drug Dosage Calculations | 1 | 2018 | 45 | 0.040 |
Why?
|
| Specimen Handling | 1 | 2020 | 307 | 0.040 |
Why?
|
| Chromosomes | 1 | 2019 | 325 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2023 | 1234 | 0.040 |
Why?
|
| Arabinonucleosides | 1 | 2020 | 470 | 0.040 |
Why?
|
| Guatemala | 1 | 2017 | 66 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2023 | 657 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2018 | 5728 | 0.040 |
Why?
|
| Peptide Fragments | 2 | 2013 | 1309 | 0.040 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2017 | 25 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2019 | 506 | 0.040 |
Why?
|
| Sleep Wake Disorders | 1 | 2020 | 372 | 0.030 |
Why?
|
| Phenotype | 2 | 2020 | 6509 | 0.030 |
Why?
|
| Etoposide | 1 | 2018 | 907 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2018 | 497 | 0.030 |
Why?
|
| Proteome | 1 | 2020 | 571 | 0.030 |
Why?
|
| Amino Acids | 1 | 2019 | 783 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2018 | 299 | 0.030 |
Why?
|
| ROC Curve | 1 | 2019 | 1248 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 7783 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2024 | 1465 | 0.030 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2021 | 875 | 0.030 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2021 | 797 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2018 | 550 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 3028 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2021 | 1101 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 2021 | 880 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 1824 | 0.030 |
Why?
|
| Computational Biology | 1 | 2021 | 1291 | 0.030 |
Why?
|
| Kidney | 1 | 2023 | 2121 | 0.030 |
Why?
|
| Lung Diseases | 1 | 2020 | 755 | 0.030 |
Why?
|
| Chromosome Banding | 1 | 2014 | 280 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2018 | 362 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 1 | 2020 | 1757 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2016 | 896 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2018 | 1608 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2018 | 13414 | 0.030 |
Why?
|
| Colony-Forming Units Assay | 1 | 2013 | 253 | 0.030 |
Why?
|
| HL-60 Cells | 1 | 2013 | 318 | 0.030 |
Why?
|
| K562 Cells | 1 | 2013 | 344 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2017 | 1099 | 0.030 |
Why?
|
| Epitope Mapping | 1 | 2013 | 110 | 0.030 |
Why?
|
| Myeloblastin | 1 | 2013 | 65 | 0.030 |
Why?
|
| Leukocyte Elastase | 1 | 2013 | 71 | 0.030 |
Why?
|
| Loss of Heterozygosity | 1 | 2014 | 623 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2022 | 1840 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2016 | 1826 | 0.030 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2013 | 202 | 0.030 |
Why?
|
| HLA-A2 Antigen | 1 | 2013 | 172 | 0.030 |
Why?
|
| Epilepsy | 1 | 2020 | 931 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2018 | 2422 | 0.030 |
Why?
|
| Disease Management | 1 | 2018 | 1090 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 2015 | 909 | 0.030 |
Why?
|
| Antigen-Presenting Cells | 1 | 2013 | 286 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2021 | 2453 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 1322 | 0.020 |
Why?
|
| Mitochondria | 1 | 2018 | 1297 | 0.020 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2017 | 1144 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2019 | 2166 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2022 | 12103 | 0.020 |
Why?
|
| Histocompatibility Testing | 1 | 2013 | 487 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2018 | 3245 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2018 | 3339 | 0.020 |
Why?
|
| Nitriles | 1 | 2015 | 939 | 0.020 |
Why?
|
| Pediatrics | 1 | 2019 | 1186 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 1525 | 0.020 |
Why?
|
| Algorithms | 1 | 2021 | 3891 | 0.020 |
Why?
|
| Biomarkers, Tumor | 2 | 2019 | 10708 | 0.020 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2013 | 1126 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2013 | 1179 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 4223 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2022 | 7381 | 0.020 |
Why?
|
| Tissue Donors | 1 | 2013 | 821 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2014 | 1568 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2015 | 4942 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 2196 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2013 | 2353 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 2224 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2023 | 4961 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 5056 | 0.020 |
Why?
|
| Protein Binding | 1 | 2013 | 3485 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2013 | 3046 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 4328 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2013 | 4329 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 5162 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2013 | 5694 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 9042 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 6177 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2015 | 3669 | 0.010 |
Why?
|
| Middle Aged | 2 | 2019 | 90352 | 0.010 |
Why?
|
| Genetic Therapy | 1 | 2004 | 1716 | 0.010 |
Why?
|
| Aged | 1 | 2019 | 73333 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2004 | 4130 | 0.010 |
Why?
|